Welcome to LookChem.com Sign In|Join Free
  • or
1-(3,5-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-ol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1082503-78-3

Post Buying Request

1082503-78-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1082503-78-3 Usage

Chemical structure

A complex chemical compound with a pyrazole ring, a boron-containing molecule, a tertiary alcohol group, and various methyl groups.

Pyrazole ring

A five-membered heterocyclic ring with alternating nitrogen and carbon atoms, contributing to the compound's unique properties.

Boron-containing molecule

The presence of a 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl group, which makes the compound useful in organic synthesis, particularly in the formation of carbon-carbon bonds.

Tertiary alcohol group

A functional group with three carbon atoms attached to the central carbon atom of the alcohol, which may contribute to the compound's reactivity and solubility.

Methyl groups

The presence of multiple methyl groups (CH3) in the compound, which can influence its steric properties and reactivity.

Steric properties

The specific arrangement of atoms in the compound may contribute to its unique steric properties, affecting its interactions with other molecules.

Potential applications

Due to its unique structure and properties, the compound may have potential applications in the field of chemistry and pharmaceuticals, such as in the development of new drugs or chemical processes.

Reactivity

The presence of various functional groups in the compound may influence its reactivity, making it a versatile building block for further chemical modifications.

Solubility

The presence of the tertiary alcohol group and multiple methyl groups may affect the compound's solubility in different solvents, which can be important for its use in chemical reactions and purification processes.

Synthesis

The compound's unique structure and properties may make it a valuable intermediate in the synthesis of more complex molecules, particularly in the formation of carbon-carbon bonds.

Check Digit Verification of cas no

The CAS Registry Mumber 1082503-78-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,2,5,0 and 3 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1082503-78:
(9*1)+(8*0)+(7*8)+(6*2)+(5*5)+(4*0)+(3*3)+(2*7)+(1*8)=133
133 % 10 = 3
So 1082503-78-3 is a valid CAS Registry Number.

1082503-78-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-[3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]-2-methylpropan-2-ol

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1082503-78-3 SDS

1082503-78-3Relevant academic research and scientific papers

Fused Bicyclic Kinase Inhibitors

-

Page/Page column 26, (2011/11/30)

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.

Optimization of a series of multi-isoform PI3 kinase inhibitors

Perry, Benjamin,Beevers, Rebekah,Bennett, Gavin,Buckley, George,Crabbe, Tom,Gowers, Lewis,James, Lynwen,Jenkins, Kerry,Lock, Chris,Sabin, Verity,Wright, Sara

scheme or table, p. 5299 - 5302 (2009/05/07)

Optimization of the cellular and pharmacological activity of a novel series of PI3 kinase inhibitors targeting multiple isoforms is described.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1082503-78-3